Process for differential diagnosis of Alzheimer's dementia and device therefor
AssigneeSyn X Pharma, Inc.
InventorsGeorge Jackowski, Miyoko Takahashi
Life of this patent
Estimating the term…
Abstract
A method for diagnosing Alzheimer's disease(AD) is disclosed. The method involves directly detecting the presence of a biochemical marker, specifically human glutamine synthetase, in bodily fluid, preferably blood or a blood product. The detection is by an immunoassay incorporating an antibody specific to human glutamine synthetase. In addition, a method for distinguishing between AD and non-AD dementia is disclosed.
Claims13
A diagnostic kit for diagnosing or monitoring the progression of Alzheimer's dementia comprising:
- at least one antibody which is specific for monomeric brain associated human glutamine synthetase having a weight of about 44 kDa, wherein said antibody is selected from the group consisting of the antibody encoded by the clone deposited with the ATCC as Accession Number PTA-3339 and the antibody encoded by the clone deposited with the ATCC as Accession Number PTA-3340,
- said antibody immobilized on a solid support.
An isolated monoclonal antibody encoded by the clone deposited with the ATCC as Accession Number PTA-3339.
An isolated antibody encoded by the clone deposited with the ATCC as Accession Number PTA-3340.
The isolated clone deposited with the ATCC as Accession Number PTA-3339.
The isolated clone deposited with the ATCC as Accession Number PTA-3340.
A method of diagnosing or monitoring the progression of Alzheimer's dementia comprising:
- obtaining a sample of blood, a blood product or cerebrospinal fluid from a patient suspected of suffering from Alzheimer's dementia;
- contacting said sample with an antibody, wherein said antibody is specific for monomeric brain associated human glutamine synthetase having a weight of about 44 kDa;
- detecting specific binding of the antibody to the sample;
- wherein detection of an elevated level of said glutamine synthetase in the sample from the patient relative to control samples indicates a diagnosis of Alzheimer's dementia, or wherein the extent of elevation of said glutamine synthetase in the sample from the patient relative to control samples correlates to the progression of Alzheimer's dementia in the patient.
Dependencies are inferred from the claim text.